Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008

BMC Infect Dis. 2016 Jun 13:16:285. doi: 10.1186/s12879-016-1627-7.

Abstract

Background: Hemolytic-uremic syndrome (HUS) is a clinical triad of microangiopathic hemolytic anemia, impaired renal function and thrombocytopenia, primarily affecting pre-school-aged children. HUS can be classified into diarrhea-associated HUS (D(+)HUS), usually caused by Shiga toxin-producing Escherichia coli (STEC), and non-diarrhea-associated HUS (D(-)HUS), both with potentially serious acute and long-term complications. Few data exists on the clinical features and long-term outcome of HUS in Norway. The aim of this paper was to describe these aspects of HUS in children over a 10-year period.

Methods: We retrospectively collected data on clinical features, therapeutic interventions and long-term aspects directly from medical records of all identified HUS cases <16 years of age admitted to Norwegian pediatric departments from 1999 to 2008. Cases of D(+)HUS and D(-)HUS are described separately, but no comparative analyses were possible due to small numbers. Descriptive statistics are presented in proportions and median values with ranges, and/or summarized in text.

Results: Forty seven HUS cases were identified; 38 D(+)HUS and nine D(-)HUS. Renal complications were common; in the D(+)HUS and D(-)HUS group, 29/38 and 5/9 developed oligoanuria, 22/38 and 3/9 needed dialysis, with hemodialysis used most often in both groups, and plasma infusion(s) were utilized in 6/38 and 4/9 patients, respectively. Of extra-renal complications, neurological complications occurred in 9/38 and 2/9, serious gastrointestinal complications in 6/38 and 1/9, respiratory complications in 10/38 and 2/9, and sepsis in 11/38 and 3/9 cases, respectively. Cardiac complications were seen in two D(+)HUS cases. In patients where data on follow up ≥1 year after admittance were available, 8/21 and 4/7 had persistent proteinuria and 5/19 and 4/5 had persistent hypertension in the D(+)HUS and D(-)HUS group, respectively. Two D(+)HUS and one D(-)HUS patient were diagnosed with chronic kidney disease and one D(+)HUS patient required a renal transplantation. Two D(+)HUS patients died in the acute phase (death rate; 5 %).

Conclusions: The HUS cases had a high rate of complications and sequelae, including renal, CNS-related, cardiac, respiratory, serious gastrointestinal complications and sepsis, consistent with other studies. This underlines the importance of attention to extra-renal manifestations in the acute phase and in renal long-term follow-up of HUS patients.

Keywords: Enterohaemorrhagic E. coli - EHEC; Epidemiology; Haemolytic uraemic syndrome; SP-HUS; Shiga toxin producing E. coli – STEC; aHUS; clinical outcome.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use*
  • Blood Transfusion*
  • Child
  • Child, Preschool
  • Diarrhea / etiology
  • Escherichia coli Infections / complications
  • Escherichia coli Infections / physiopathology
  • Escherichia coli Infections / therapy*
  • Female
  • Heart Diseases / etiology
  • Hemolytic-Uremic Syndrome / complications
  • Hemolytic-Uremic Syndrome / physiopathology
  • Hemolytic-Uremic Syndrome / therapy*
  • Humans
  • Hypertension / etiology
  • Infant
  • Kidney
  • Kidney Failure, Chronic / etiology
  • Kidney Transplantation
  • Male
  • Nervous System Diseases / etiology
  • Norway
  • Plasmapheresis*
  • Proteinuria / etiology
  • Renal Dialysis
  • Renal Insufficiency, Chronic / etiology
  • Renal Replacement Therapy*
  • Respiration, Artificial*
  • Respiratory Tract Diseases / etiology
  • Retrospective Studies
  • Sepsis / etiology
  • Shiga-Toxigenic Escherichia coli

Substances

  • Anti-Bacterial Agents